Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03269604
Other study ID # 1075237598
Secondary ID
Status Recruiting
Phase N/A
First received August 30, 2017
Last updated January 22, 2018
Start date January 22, 2018
Est. completion date November 2018

Study information

Verified date January 2018
Source CES University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Asymptomatic bacteriuria (AB) is the isolation of a bacterium in a sample of urine appropriately collected from a person who does not have signs or symptoms of urinary infection. It is common in diabetic women, in pregnant women, in men over 60 years and in patients with spinal cord injury.

There is clinical evidence that AB should be treated in patients who will be operated on with urologic surgery because of the risk of presenting infectious complications; however, the timing of initiating antibiotic therapy has not been established, even in some studies the prophylaxis has been considered from one to seven days prior to the procedure, without determining the differences in the outcome for each one of the interventions and causing an undue and risky use of antibiotics.

A randomized, parallel-design, single-masked clinical trial will be performed to compare and analysis the bloodstream infections, surgical site infections, readmissions and hospital stay in three intervention groups, 1) those receiving antibiotics during the previous 5 days to the procedure; 2) 3 days prior to the procedure; and 3) those who receive only a single dose of antibiotic on the day of the procedure.

The main expected result is to identify the timing of initiation of antibiotic prophylaxis in urological procedures in patients with asymptomatic bacteriuria, with the purpose of diminishing the bloodstream and of the surgical site infections. If it is scientifically demonstrated that those patients who receive a single dose of antibiotic on the same day of the procedure, have the same safety and effectiveness compared to the other two groups, would reduce hospital stay, surgical waiting time and indiscriminate use of antibiotics that generate multidrug-resistant microorganisms, thus generating an impact on Public Health and on the quality of care.


Recruitment information / eligibility

Status Recruiting
Enrollment 456
Est. completion date November 2018
Est. primary completion date October 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age = 18 years

- Patients with asymptomatic bacteriuria identified with a urine culture prior to the surgical procedure and with a microorganism that meets the following criteria: 1) gram-negative bacteria in the enterobacterial family and non-fermenting bacilli; 2) Bacteria with resistance profile has a therapeutic option that reaches therapeutic concentration in urine.

- Patients scheduled for urological procedures, such as: transurethral resection of the prostate, open prostatectomy, cystoscopy, extracorporeal lithotripsy and flexible ureterorenoscopy.

- Informed consent

Exclusion Criteria:

- Patients with chronic renal failure; with immunosuppressive status secondary to glucocorticoid consumption, haematological or solid organ neoplasms undergoing chemotherapy or radiation therapy or neutropenia.

- Patients with active infection or clinical criteria of urinary infection.

- Patients who voluntarily do not want to participate in the study.

- Patients who can not give informed consent under reasonable or vulnerable conditions.

- Patients who present type I allergy to penicillin.

- Patients who have scheduled surgeries combined with a discipline different to urology.

Study Design


Intervention

Procedure:
Prophylactic antibiotic during five days previous to the procedure
Prophylactic antibiotic during five days previous to the procedure.
Prophylactic antibiotic during three days previous to the procedure
Prophylactic antibiotic during three days previous to the procedure.
Only a single dose of Prophylactic antibiotic
This group will receive a single dose of antibiotic 90 ± 20 minutes prior to the start of the surgical procedure (incision)

Locations

Country Name City State
Colombia Universidad CES Medellín Antioquia

Sponsors (1)

Lead Sponsor Collaborator
Jorge Andres Ramos Castaneda

Country where clinical trial is conducted

Colombia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Bloodstream infection An infectious process characterized by the presence of some bacteria in the bloodstream. The patient should have one or more positive blood cultures, where the cultured organism is not related to an infection elsewhere, and has signs of infection, such as fever, hypotension or tachycardia. 30 days
Secondary Surgical Site Infection: It can occur up to 30 days (or a year when a prosthetic component is involved) of a surgical procedure in some part of the body where it was manipulated in surgery. The SSI is classified as superficial, deep or organ space, depending on the type of tissue involved. 30 days
Secondary Length of hospital stay Difference in days between the date of discharge and of the surgical procedure. 30 days
Secondary Re-entry to hospitalization Re hospitalization after the surgical procedure due to SSI or bloodstream. 30 days
See also
  Status Clinical Trial Phase
Terminated NCT03028129 - Prevention of Tuberculosis in Prisons Phase 4
Completed NCT05612542 - Pediatric Cardiac Surgery Comparing Short 24-hour Antibiotic Prophylaxis to Extended Antibiotic Prophylaxis
Completed NCT03765645 - Comparison of 9 Doses vs 3 Doses of Post Operative Antibiotics in Live Liver Donors N/A
Completed NCT03306290 - Serum Concentration of CEFOxitin Used for Antibiotic Prophylaxis in Obese Patients Undergoing BARiatric Surgery N/A
Recruiting NCT03283878 - Antibiotic Prophylaxis in Patients Undergoing Elective TKA- Multi-center Trial Phase 4
Not yet recruiting NCT05438082 - Antibiotic Prophylaxis to Prevent Post-procedure UTI After VCUG Phase 4
Recruiting NCT05654896 - Prophylactic Antibiotic Use in Transarterial Chemoembolization for Hepatocellular Carcinoma Phase 3
Recruiting NCT05609240 - Colo-Pro_2: Bolus-continuous Infusion Cefuroxime Prophylaxis for the Prevention of Infections After Colorectal Surgery Phase 2
Withdrawn NCT04280237 - Pharmacological Study of Cefazolin Antibioprophylaxis in Liver Transplantation
Completed NCT02479503 - Antibiotic Prophylaxis in Adult Heart Transplantation: a French National Survey
Completed NCT00818766 - Efficacy of Post-operative Antibiotic Prophylaxis for Thoracic Surgery Requiring Tube Thoracostomy. N/A
Recruiting NCT05755789 - Intermittent Cefoxitin Administration Versus Loading Bolus Followed by Continuous Infusion for the Prevention of Surgical Site Infection in Colorectal Surgery Phase 3
Withdrawn NCT01880112 - Serum and Tissue Cefazolin Concentrations in Normal Weight Patients Undergoing Cesarean Delivery. Phase 4
Withdrawn NCT03982810 - The Role of Guideline-adherent Perioperative Antibiotic Administration and the Risk of Surgical Site Infections After Non-cardiac Surgery.
Terminated NCT03386227 - Prophylactic Antibiotics Prior to Embryo Transfer (PAPET): RCT N/A
Completed NCT02809729 - Antibiotic Prophylaxis in Oncological Surgery of Breast N/A
Completed NCT03412305 - The Effect of Antibiotic Prophylaxis Associated With Dental Implant Surgery Phase 4
Completed NCT03790254 - D Mannose for Prevention and Treatment of RUTIs
Recruiting NCT05519072 - Use of Prophylactic Antibiotics Prior to OnabotulinumtoxinA Phase 4
Not yet recruiting NCT05813184 - Prenatal Antibiotics and Breast Milk / Neonatal IgA